Clinical Trial

Descemet Endothelial Thickness Comparison Trial II

Study acronym: DETECT II
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Descemet Endothelial Thickness Comparison Trial (DETECT) II is a multi-center, outcome assessor-masked, placebo-controlled clinical trial randomizing 60 patients with Fuchs endothelial dystrophy to DMEK versus Descemet Stripping Only (DSO) with adjunctive Ripasudil.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2022-03-02; most recent amendment 2026-05-06.
Status change: Not Yet Recruiting → Recruiting 2022-08-23
Trial Details
NCT Number NCT05275972
Lead Sponsor Stanford University
Collaborators: Oregon Health and Science University, University of California, San Francisco, University of California, Davis, Case Western Reserve University, Dartmouth-Hitchcock Medical Center, University of Pennsylvania, University of Miami, Wills Eye Hospital, Devers Eye Institute
Conditions Fuchs, Fuchs Dystrophy, Fuchs' Endothelial Dystrophy
Enrollment 60 participants
Start Date 2023-01-23
Primary Completion 2027-11-30 (estimated)
Study Completion 2028-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-08